Amarin enters the home stretch
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
Medtech venture investors wait longer for an exit
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
AASLD 2019 – Assembly asks investors to keep the faith
Firmer evidence to support Assembly’s approach to vanquishing the hepatitis B virus will not emerge until next year, and rivals are not standing still in the meantime.
Medtech
Medtech venture investors wait longer for an exit
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
Company Events
Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Iterum’s antibiotic is far from a Sure thing
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
Interviews
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.